FibroBiologics Completes Manufacturing Of Third Batch Of CYWC628 Drug Product For Ongoing Phase 1/2 Clinical Trial In Patients With Diabetic Foot Ulcers

Loading news article.

FibroBiologics Completes Manufacturing Of Third Batch Of CYWC628 Drug Product For Ongoing Phase 1/2 Clinical Trial In Patients With Diabetic Foot Ulcers | WAPE

FibroBiologics Completes Manufacturing Of Third Batch Of CYWC628 Drug Product For Ongoing Phase 1/2 Clinical Trial In Patients With Diabetic Foot Ulcers

Article summary

Related companies

Comments —